Double-Targeting immune cells tested as potential lifeline for tough lymphomas
NCT ID NCT04697940
Summary
This study is testing a new type of CAR T-cell therapy for adults with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own modified immune cells designed to attack two common targets on lymphoma cells (CD19 and CD20). The main goals are to find a safe dose and see if this approach can effectively control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.